An Effective Agent for Systemic-Onset Juvenile Idiopathic Arthritis?
An Effective Agent for Systemic-Onset Juvenile Idiopathic Arthritis?
Quartier P, Allantaz F, Cimaz R, et al
Ann Rheum Dis. 2011;70:747-754
Systemic-onset juvenile idiopathic arthritis (SJIA) is rare but it can be a devastating disease that responds poorly to therapy. Case series have suggested that the interleukin-1 receptor antagonist anakinra may be beneficial in this disease; however, randomized, controlled trials evaluating its efficacy in SJIA are lacking. These authors performed a randomized, placebo-controlled trial to evaluate the short-term efficacy of anakinra in SJIA.
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Trial With the Interleukin-1 Receptor Antagonist Anakinra in Patients With Systemic-Onset Juvenile Idiopathic Arthritis (ANAJIS trial)
Quartier P, Allantaz F, Cimaz R, et al
Ann Rheum Dis. 2011;70:747-754
Background
Systemic-onset juvenile idiopathic arthritis (SJIA) is rare but it can be a devastating disease that responds poorly to therapy. Case series have suggested that the interleukin-1 receptor antagonist anakinra may be beneficial in this disease; however, randomized, controlled trials evaluating its efficacy in SJIA are lacking. These authors performed a randomized, placebo-controlled trial to evaluate the short-term efficacy of anakinra in SJIA.
